Please assess the completion status of the following clinical trial:

Trial Title: Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects diagnosed with mild to moderate COPD (GOLD stage I, II and III)-~* 10 pack-year smoking history or greater and ceased to smoke at least for 2 months prior to recruitment~* Subjects taking H2 antagonists, Imodium or loratadine and willing to stop during the study period~Exclusion criteria:~* COPD subjects with \>80% or \<35% predicted~* Current smokers~* Known allergy/sensitivity to quercetin~* Subjects with primary diagnosis of asthma~* Upper respiratory tract infection within two weeks of the screening visit~* Acute bacterial infection requiring antibiotics within two weeks of screening~* Emergency treatment or hospitalization within one month of screening~* Pregnant or lactating mothers~* Women who don't consent to take pregnancy test~* Unwillingness to stop flavonoid supplementation~* Dietary intake exceeding or averaging 150 mg quercetin daily as assessed by Bioflavonoid Food and Supplement Screener~* Daily oral steroid treatment, warfarin, cyclosporine (neural, sandimmune), digoxin, fexofenadine, paclitaxel, diltiazem, saquinavir, selected chemotherapeutic agents (etoposide, vinblastine, vincristine, vindesine), antifungals (ketoconazole, itraconazole), protease inhibitors (amprenavir, indinavir, nelfinavir), verapamil, oral glucocorticoids, erythromycin, quinidine~* Subjects taking H2 antagonists (cimetidine, ranitidine), loperamide (Imodium) or loratadine and not willing to stop during study period~* Lung cancer history or undergoing chemo- or radiation therapy~* Inflammatory bowel disease~* Child bearing age, who are unwilling to use adequate contraception or abstain during the course of the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sugar chew-Cohort 1 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin
- Quercetin 1-Cohort 1 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Quercetin 2-Cohort 2 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Quercetin 3-Cohort 3 (Type: ACTIVE_COMPARATOR): Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
- Sugar chew-Cohort 2 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin
- Sugar Chew-Cohort 3 (Type: PLACEBO_COMPARATOR): contains 350 mg of vitamin C and 10 mg niacin

Based on this trial design, predict the completion outcome and termination type (if applicable).